Recommended Systemic Treatment for Advanced HCC
For patients with hepatocellular carcinoma ineligible for curative-intent surgery or ablation, atezolizumab plus bevacizumab is the preferred first-line systemic therapy 1, 2.
First-Line Treatment Algorithm
The 2024 ASCO guidelines establish atezolizumab plus bevacizumab as the standard of care for advanced HCC based on the IMbrave150 trial, which demonstrated superior overall survival, progression-free survival, and response rates compared to sorafenib 1. This combination has become the benchmark against which other regimens are measured.
Alternative First-Line Options
If atezolizumab plus bevacizumab is contraindicated or unavailable, consider:
- Durvalumab plus tremelimumab (single dose): The HIMALAYA trial showed improved overall survival compared to sorafenib, making this a viable alternative dual immunotherapy option 1
- Lenvatinib: Non-inferior to sorafenib in first-line setting 3, 4
- Sorafenib: Historical standard, now considered when immunotherapy combinations are not feasible 1, 3
Critical Pre-Treatment Considerations
Before initiating atezolizumab plus bevacizumab, you must:
- Screen for and manage esophageal varices according to institutional protocols due to bleeding risk with bevacizumab 1
- Assess bleeding and thrombosis risk given VEGF inhibitor effects 1
- Evaluate for active or prior autoimmune disease, as this increases risk of immune-related adverse events with checkpoint inhibitors 1
- Confirm Child-Pugh A status and ECOG performance status 0-1, as approximately 80% of trial patients had these characteristics 1
Patient Selection Factors
The choice between first-line options should account for 1:
- Medical comorbidities (particularly cardiovascular disease, bleeding disorders, autoimmune conditions)
- Treatment-related toxicity profiles
- Cost and access considerations
- Patient goals and preferences
- Expected treatment benefit based on liver function and performance status
Second-Line Treatment Options
If disease progresses on first-line therapy, evidence supports 1, 4:
- Regorafenib: Proven survival benefit in second-line setting
- Cabozantinib: Demonstrated efficacy after prior systemic therapy
- Ramucirumab: Option for patients with AFP ≥400 ng/mL
Common Pitfalls to Avoid
- Do not delay variceal screening before starting bevacizumab-containing regimens—bleeding complications can be catastrophic
- Do not use immunotherapy in patients with decompensated cirrhosis (Child-Pugh B/C)—these patients were excluded from pivotal trials 1
- Do not assume all patients are candidates for combination therapy—approximately 60% of trial patients had ECOG PS 0, indicating highly selected populations 1
Evidence Quality Context
The 2024 ASCO guideline 1 and 2025 EASL guideline 2 represent the highest quality evidence, both incorporating multiple phase III randomized controlled trials. The IMbrave150 trial data showing superior outcomes with atezolizumab plus bevacizumab has been consistently validated across international guidelines, making this the most robust recommendation for first-line therapy in appropriate candidates.